GSK vows to disclose payments to docs; details to come

Share this article:
GlaxoSmithKline plans to disclose payments to US physicians and impose a cap of $150,000 per year, per doctor, but details of the disclosure scheme are still being worked out.

GSK CEO Andrew Witty outlined the cap-and-publish policy to The Financial Times earlier in the week, saying that: “It's appropriate that we have a limit on what we pay. In the past, whatever has happened has happened, but in the future there will be strict adherence to these caps, which will be clearer to everybody.

Pressed for specifics, GSK said in a statement that it is “committed to making information about physician payments publicly available in the US. We are urgently undertaking a review of our internal processes to determine the best way to efficiently and accurately collect this information. We will be putting a process in place to ensure this information can be reported as soon as possible.”

The company's payments to Emory University's Dr. Charles Nemeroff, a prominent psychiatrist, were the subject of a recent investigation by Sen. Charles Grassley's Committee on Finance. Nemeroff resigned his position as chair of the university's psychiatry department after it was revealed that he had underreported fees from GSK.

Earlier this month, it was reported that the Dutch health inspectorate raided the offices of GSK and Sanofi-Aventis over alleged payments to physicians advising the government on health policy issues – including vaccinating girls against cervical cancer. GSK makes the Cervarix HPV vaccine, while Sanofi is handling European commercialization of Merck's Gardasil.

GSK noted that the disclosure policy, which would apply only to payments to US physicians, is irrelevant to the Dutch investigation.

Last month, Lilly announced it would disclose payments to physicians. In August, GSK said it would publish information on its CME grants, as Lilly and other companies had done.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...